International Patent: SEQUENCE MODIFICATION OF RECOMBINANT BOTULINUM NEUROTOXIN TYPE A2 AND USE THEREOF

GENEVA, June 26 -- SUZHOU DENEUGEN BIOTECHNOLOGY CO., LTD filed a patent application (CN2025/138540) for “SEQUENCE MODIFICATION OF RECOMBINANT BOTULINUM NEUROTOXIN TYPE A2 AND USE THEREOF”. With publication no. WO/2026/119031, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C07K 14/33

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....